Alkermes Engages in Insights at Annual Neuropsychiatry Conference
Alkermes to Engage in Key Neuropsychiatry Conference
Alkermes plc (Nasdaq: ALKS) has recently announced its participation in a significant event in the field of neuroscience. This year's TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Conference is set to provide a platform for discussing innovative approaches to mental health treatments.
What to Expect from the Conference
During the conference, the management team at Alkermes will hold a fireside chat presentation. The event is scheduled for a date in September, and the discussion will revolve around cutting-edge developments in neuropsychiatry and the role of Alkermes in advancing treatment options.
Live Webcast Availability
The live presentation is open for public access through the Investors tab on Alkermes’ official website, allowing individuals to tune in and benefit from the insights shared. Additionally, the webcast will be archived for those who are unable to attend live but wish to catch up on the discussions later.
About Alkermes plc: A Leader in Neuroscience
Alkermes plc stands out as a global biopharmaceutical company committed to developing innovative therapeutic solutions targeted at neurological disorders. The company's portfolio features proprietary commercial products for treating alcohol and opioid dependence, schizophrenia, and bipolar I disorder. In addition to these treatments, Alkermes is actively working on a pipeline of clinical and preclinical candidates aimed at addressing specific neurological conditions, including narcolepsy.
Global Presence and Commitment to Innovation
Headquartered in Ireland, Alkermes also maintains a research and development center and corporate office in Massachusetts alongside a state-of-the-art manufacturing facility in Ohio. This strategic setup supports their dedication to innovation and ensuring that they remain at the forefront of advancements in neuroscience.
Connect with Alkermes
The commitment of Alkermes to addressing serious neurological challenges makes it a pivotal player in the biopharmaceutical sector. Stakeholders and interested parties are encouraged to connect and learn more about the company's vision and contributions to neuroscience through their website.
Contact Information
For inquiries, Alkermes has a dedicated Investor Relations team led by Jamie Constantine. Potential investors and interested parties can reach out directly via phone at +1 781 873 2402.
Frequently Asked Questions
What is the TD Cowen 4th Annual Neuropsychiatry Conference?
The conference focuses on innovative mechanisms in neuropsychiatry, spotlighting advanced treatment options and research in the field.
When is Alkermes participating in the conference?
Alkermes is scheduled to participate in the conference in September, with specific timings for their presentation, which will be shared publicly.
How can I access the conference webcast?
The live webcast will be accessible via Alkermes' official website, specifically under the Investors tab, and will be available on-demand for 14 days post-event.
What types of treatments does Alkermes develop?
Alkermes develops treatments for conditions like alcohol and opioid dependence, schizophrenia, and bipolar I disorder, as well as other neurological disorders.
Who can I contact for more information about Alkermes?
For more detailed inquiries, you can reach out to Jamie Constantine in the Investor Relations department at Alkermes.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.